GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Enterprise Value

XORTX Therapeutics (XORTX Therapeutics) Enterprise Value

: $3.88 Mil (As of Today)
View and export this data going back to 2018. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, XORTX Therapeutics's Enterprise Value is $3.88 Mil. XORTX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.42 Mil. Therefore, XORTX Therapeutics's EV-to-EBIT ratio for today is -0.88.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, XORTX Therapeutics's Enterprise Value is $3.88 Mil. XORTX Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.29 Mil. Therefore, XORTX Therapeutics's EV-to-EBITDA ratio for today is -0.91.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, XORTX Therapeutics's Enterprise Value is $3.88 Mil. XORTX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, XORTX Therapeutics's EV-to-Revenue ratio for today is .


XORTX Therapeutics Enterprise Value Historical Data

The historical data trend for XORTX Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Annual Data
Trend Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Premium Member Only Premium Member Only Premium Member Only 5.62 8.22 9.28 11.84 1.81

XORTX Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.92 1.81 0.52 5.56 5.75

Competitive Comparison

For the Biotechnology subindustry, XORTX Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XORTX Therapeutics Enterprise Value Distribution

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Enterprise Value falls into.



XORTX Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

XORTX Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

XORTX Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XORTX Therapeutics  (NAS:XRTX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

XORTX Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3.882/-4.42
=-0.88

XORTX Therapeutics's current Enterprise Value is $3.88 Mil.
XORTX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.42 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

XORTX Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=3.882/-4.285
=-0.91

XORTX Therapeutics's current Enterprise Value is $3.88 Mil.
XORTX Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.29 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

XORTX Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3.882/0
=

XORTX Therapeutics's current Enterprise Value is $3.88 Mil.
XORTX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XORTX Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


XORTX Therapeutics (XORTX Therapeutics) Business Description

Traded in Other Exchanges
Address
3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

XORTX Therapeutics (XORTX Therapeutics) Headlines